INTRODUCTION
Lipophilic drug molecules and metabolites are eliminated through the bile from the human body. The bile contains a highly concentrated solution of bile salts, biliary lipids (phospholipids and cholesterol) and electrolytes. The concentration of these components can be 500-1000 times greater in the bile than in hepatocytes. The active transport process mediating canalicular solute transport (which generates bile flow) relies on the activity of efflux transporters in the canalicular membrane, i.e. BSEP (ABCB11), MRP2 (ABCC2), MDR3 (ABCB3) and ABCG5/8 (Arrese, 2003; Pauli-Magnus, 2006) . BSEP/Bsep is a member of the ATP binding cassette (ABC) transporter protein family.
It was first cloned in 1998 from rat and identified as the "sister of Pgp", a name previously proposed for its close similarity in amino acid sequence to Pgp (Gerloff, 1998) .
It is a highly conserved protein, the amino acid similarity between the human and the skate protein is 68% (Cai, 2001) . The rat and mouse orthologs of the human BSEP are also close relatives sharing 82% and 80% similarity, respectively (Green, 2000; Lecureur, DMD #24778 Ci/mmol) and 3 H-glycochenodeoxycholate ( 3 H-GCDC) (SA: 14.0 Ci/mmol) were synthesized as described by reductive tritiation of the ∆ 22,23 precursor (Sorscher, 1992) and kindly provided by Dr. Alan F. Hofmann (University of California, San Diego). The recombinant baculoviruses encoding wild-type BSEP, mouse Bsep and rat Bsep and a polyclonal antibody against the C-terminus of BSEP, K24 (Noe, 2002) , were kindly provided by Bruno Stieger, (University Hospital, Zürich, Switzerland) . Cholesterol complex of RAMEB (cholesterol@RAMEB) was a product of Cyclolab (Budapest, Hungary). Unlabeled TC, GC, TCDC, GCDC and all other chemicals and reagents were purchased from Sigma-Aldrich, unless stated otherwise in the text.
MATERIALS AND METHODS

Materials
Membrane preparation and cholesterol loading
Insect membrane vesicles were produced using Sf9 insect cells infected with recombinant baculoviruses listed above. Sf9 cells were cultured and infected with a recombinant baculovirus stock as described earlier (Pal, 2007 (Pal, 2007) . Cholesterol treated membranes are indicated as "HAM" (High Activity Membranes) hereinafter.
SDS-PAGE, Western Blotting and Coomassie Blue staining
The detailed protocol for Western blotting is described elsewhere (Pal, 2007) . In brief, 6
μg total protein per sample was loaded per lane. The primary antibody, described in the Materials section, was used in a 1:500 dilution in blocking buffer, while the secondary antibody, sheep anti-rabbit IgG-HRP, a horseradish peroxidase-conjugated speciesspecific whole antibody (Sigma-Aldrich) was used in a 1:5000 dilution in TPBS.
An antibody against α-actin (dilution 1:500) was used as a control for lane loading discrepancy. The secondary antibody was sheep anti-rabbit IgG-HRP (dilution 1:10000).
For semi-quantitative determination of BSEP/Bsep in the samples, 15 μg (total) protein was separated on 7.5% polyacrylamide gel and stained with Coomassie blue. Bovine gamma globulin, a 140 kDa protein (Fermentas UAB, Vilnius, Lithuania), was used as internal standard for the calibration curve (1.25 -5 μg / well). For visualization and quantification ImageJ (NIH, Bethesda, MD, USA) software was used.
Vesicular Transport Assay
This article has not been copyedited and formatted. The final version may differ from this version. µg total protein and 2.2 µg /15 µg total protein, respectively) and the rat protein expression was about half of that (1.3 µg /15 µg total protein). Cholesterol treatment had no effect on the amount of transporter in the preparations.
RESULTS
Cholesterol
Cholesterol stimulates BSEP/Bsep activity, but does not change K M values
The species specific transport of four different bile salts was investigated: TC, TCDC, GC and GCDC. All bile salts showed saturable transport, following Michaelis-Menten kinetics. Cholesterol-loading increased the V max values in all cases ( Table 1 ). The bile salt transport of beta-galactosidase containing control vesicles (β-gal-Sf9) was negligible, irrespective of cholesterol treatment (data not shown).
Linearization of TC transport by human, mouse and rat proteins is shown in Figure 3 . No significant change was observed in the K M values as indicated by the parallel curves. The species and substrate specific maximal difference in K M values varied around 3-fold in both cholesterol treated and untreated membranes ( Table 1) . As shown in Table 1 the species specific ranking of K M values for bile salts were similar for untreated membranes.
GCDC displayed the highest affinity and GC had the lowest affinity. Only in the case of the rat transporter did cholesterol treatment modulate this order, where treatment increased the uniformity of the K M values (Table 1 ). The ranking of intrinsic clearance values slightly vary between species (TCDC~GCDC>TC~GC, TC>GCDC~TCDC>GC, TCDC~GCDC>TC~GC for human, mouse and rat, respectively); cholesterol loading caused a small change only for rat Bsep (TC>GC~TC~GCDC) ( Table 1) . Intrinsic clearance values of control and cholesterol-treated vesicles were correlated ( Figure 4 ).
The slopes of the curves were 1.26 ± 0.34, 1.48 ± 0.12, and 2.83 ± 1.34 for human BSEP, mouse Bsep and rat Bsep, respectively. This indicates that upon cholesterol loading the most pronounced effect was in the case of the rat protein, while the activity of human BSEP was least affected by the treatment.
Cholestatic compounds inhibit the transport of bile salts to various extents
This article has not been copyedited and formatted. The final version may differ from this version. 18.9 μM respectively). The species specific inhibitory profiles of troglitazone and glibenclamide were more uniform.
Species specific bile salt transport is affected differently by cholestatic compounds
Even though the inhibition profiles of troglitazone ( Figure 6 ) and glibenclamide (data not shown) are similar within one species, there are species specific differences in the calculated IC 50 values (Table 2) . There is about an order of magnitude difference in the affinity of glibenclamide for the human and the mouse transporter. IC 50 values ranged from 7.6 to 18.8 μM for the human transporter and 95.5 to 153 μM for the mouse transporter ( Table 2 ). The corresponding ranges for troglitazone are 9.5 to 27.6 μM for the human protein and 40.4 to 63.4 μM for the mouse protein. Such a trend could not be observed for CsA. For this compound the largest interspecies difference in IC 50 values was obtained for TCDC and the lowest for GC (with ranges of 0.09 μM -7.17 μM and 0.93 μM -2.28 μM, respectively).
Cholesterol loading of Sf9 vesicles does not influence the kinetic parameters of BSEP inhibitors
This article has not been copyedited and formatted. The final version may differ from this version. For studying Bsep-mediated interactions, besides the intricate system of sandwich cultured hepatocytes, the vesicular transport assay is used most commonly. The first vesicular transport studies utilized canalicular membrane vesicles (CMV). The CMV is a popular model (Meier 1984; Funk, 2001; Bode, 2002) , as this system contains all the relevant canalicular transporters at an expression level close to physiological. In addition, Mrp2 null rat strains (Jansen, 1985; Paulusma, 1996; Hosokawa, 1992; Ito, 1997; Xiong, 2000) as well as Mrp2 (Chu, 2006) (Byrne, 2002; Gerloff, 1998 , Noe, 2002 , Stieger, 2000 . Inherent limitations, such as improper protein glycosylation and low membrane cholesterol content (Pal, 2007) must be taken into consideration.
While underglycosylation does not seem to affect the function of ABC transporters (Pal, 2007; Ozvegy, 2002; Bakos, 2000) membrane cholesterol has been reported to modulate the activity of several ABC transporters localized preferably in cholesterol-rich microdomains of apical membranes (Bacso, 2004; Tietz, 2005; Storch, 2007 values of the rat transporter are closer to the relevant data on the human transporter. For troglitazone, the IC 50 values for the rat protein are closer to the data on the mouse protein (Table 2) .
Our results correlate reasonably well with published data. In the case of the human BSEP-mediated TC transport inhibition the difference between our data and published results is about twofold for both glibenclamide and CsA (Byrne, 2002) . For rat
Bsep mediated TC transport inhibition 3-6-fold differences are observed compared to our This article has not been copyedited and formatted. The final version may differ from this version. results (Stieger, 2002 and Funk, 2001 ). However, the rankings are the same (CsA<troglitazone~glibenclamide) in all studies.
To ensure that the obtained IC 50 values are valid, we tested a small set of compounds (nine altogether) for their abilities to inhibit BSEP-mediated TC transport in both control and cholesterol-loaded Sf9 vesicles containing human BSEP. The set included the three compounds in focus as well. All compounds inhibited TC transport with near identical IC 50 values for the respective compounds in the membrane vesicles with different cholesterol content ( Table 3 ). The only outlier was CsA, where a difference close to 10-fold could be observed. The fact that only this compound was affected by the increased cholesterol content of the system further highlights the special behavior of CsA towards BSEP. Not only was this the compound showing the greatest inter-species and bile salt variability, but also -for yet unknown reasons -this was the one apparently sensitive for the cholesterol content of the membrane.
The cholesterol content of our cholesterol loaded membrane is 0.16 µmol cholesterol / mg membrane protein that is close to data published in the literature for human (0.36 µmol cholesterol / mg membrane protein) and rat (0.45 µmol cholesterol / mg membrane protein) canalicular membranes (Ahmed, 1995 and Meier, 1984, respectively) Caveolin -1 has been shown to co-localize with ABCB1 (Troost, 2004) and co-precipitate with ABCG2 (Storch, 2007) . In addition, due to cholesterol depletion both ABCB1 and caveolin-1 from detergent resistant membrane fractions diminished in a manner reversible by cholesterol repletion (Troost, 2004) . It is tempting to speculate that cholesterol promotes ABCB1 -caveolin-1 complex formation and activity. However, the effect of caveolin-1 on ABCB1 activity is rather controversial (reviewed in Orlowski, 2006) . It is also unlikely that cholesterol exerts its effects through the modulation of partitioning into the lipid membranes as changes of membrane cholesterol per se did not cause membrane accumulation or extrusion of substrates (Troost, 2004) . It is also unlikely that highly hydrophilic substrates would be transported from a binding site embedded in the lipid bilayer (Pal, 2007) . In sum, it is likely that cholesterol is either an allosteric modulator of ABC transporters or simply acts via changing membrane fluidity.
In summary, we have shown that cholesterol treatment has a marked effect on BSEP/Bsep activity, namely, it increases V max values, without producing the same shift in K M values. The significance of our findings is twofold. On the one hand we are showing that albeit cholesterol makes BSEP/Bsep work more efficiently, cholesterol loading for the most important substrates does not change the affinity for the transporter making all data generated on cholesterol poor native Sf9 membranes still valid. Cholesterol loading did not affect the inhibitor potencies with the exception of CsA. On the other hand, the species specificity of inhibitors (Table 2) is much greater than what would be expected from the moderate interspecies variation in the substrate kinetics (Table 1) .
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